golimumab IBD
Selected indexed studies
- AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis. (Gastroenterology, 2024) [PMID:39572132]
- A comprehensive review and update on Crohn's disease. (Dis Mon, 2018) [PMID:28826742]
- Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. (Nat Med, 2017) [PMID:28368383]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials. (2022) pubmed
- A comprehensive review and update on Crohn's disease. (2018) pubmed
- AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis. (2024) pubmed
- Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. (2017) pubmed
- Therapeutic drug monitoring in inflammatory bowel disease: recent developments. (2024) pubmed
- Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan. (2023) pubmed
- Next-Generation Therapeutics for IBD. (2015) pubmed
- Spondyloarthritides. (2011) pubmed
- Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study. (2021) pubmed
- Golimumab for ulcerative colitis: adding perspective to the pursuit. (2018) pubmed